Evidence map›Paper›PMID 33093774›Full record

ReviewSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2020

Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy.

Huzaefah Syed, Christian Ascoli, Catharina Fm Linssen, Christen Vagts, Thomas Iden, Aamer Syed, Jordana Kron, Kelly Polly, David Perkins, Patricia W Finn and 4 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Observational
  2. Article
  3. Contemporary management of sarcoidosis.Frontiers in medicine · 2026
    Review
  4. Review
  5. Article
  6. Infectious Complications of Pulmonary Sarcoidosis.Journal of clinical medicine · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Controversies in the Treatment of Cardiac Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022
    Article
  12. Tackling Health Care Disparities: How to Build a Sarcoidosis Center.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022
    Review
  13. Review
  14. Review
  15. Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Huzaefah SyedDivision of Rheumatology, Allergy, and Immunology, Virginia Commonwealth University, Richmond, VA, USA.
Christian AscoliDivision of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL, USA.
Catharina Fm LinssenDepartment of Medical Microbiology, Zuyderland Medical Centre, Heerlen/Sittard-Geleen, the Netherlands.
Christen VagtsDivision of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL, USA.
Thomas IdenDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
Aamer SyedDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
Jordana KronPauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Kelly PollyDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, VA, USA.
David PerkinsDivision of Nephrology, University of Illinois at Chicago, Chicago, IL, USA.
Patricia W FinnDivision of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL, USA.
Richard NovakDivision of Infectious Diseases, University of Illinois at Chicago, Chicago, IL, USA.
Marjolein DrentILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands.
Robert BaughmanDepartment of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.
Nadera J SweissDivision of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL, USA.
University of Illinois Chicago · USVirginia Commonwealth University · USSt. Antonius Ziekenhuis · NLUniversity of Cincinnati · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcoidosis is a systemic inflammatory disease characterized by granuloma formation in affected organs and caused by dysregulated immune response to an unknown antigen. Sarcoidosis patients receiving immunosuppressive medications are at increased risk of infection. Lymphopenia is also commonly seen among patient with sarcoidosis. In this review, risk of infections, including opportunistic infections, will be outlined. Recommendations for vaccinations and prophylactic therapy based on literature review will also be summarized.

Indexed as

Immunocompromised HostVaccinationHost-Pathogen InteractionsHumansImmunization ScheduleImmunosuppressive AgentsOpportunistic InfectionsRisk FactorsSarcoidosisTreatment OutcomeImmunosuppressive Agentsimmunizationsinfectionsopportunistic infectionsprophylaxisSarcoidosistravelvaccinations

Identifiers

PMID33093774
PMCPMC7569559
OpenAlexW3094141296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.